SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data-Reference-Cited by-同舟云学术

SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data

Published:2021-07-08 Issue:27 Volume:26 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Nguyen Dung¹,Simmonds Peter¹,Steenhuis Maurice²,Wouters Elise³,Desmecht Daniel⁴,Garigliany Mutien⁴,Romano Marta⁵,Barbezange Cyril⁶,Maes Piet⁷,Van Holm Bram⁷,Mendoza Joaquín⁸,Oyonarte Salvador⁹,Fomsgaard Anders¹⁰,Lassaunière Ria¹⁰,Zusinaite Eva¹¹,Resman Rus Katarina¹²,Avšič-Županc Tatjana¹²,Reimerink Johan HJ¹³,Brouwer Fiona¹³,Hoogerwerf Marieke¹³,Reusken Chantal BEM¹³,Grodeland Gunnveig¹⁴,Le Cam Sophie¹⁵,Gallian Pierre¹⁶¹⁵,Amroun Abdennour¹⁶,Brisbarre Nadège¹⁷¹⁶,Martinaud Christophe¹⁸,Leparc Goffart Isabelle¹⁹,Schrezenmeier Hubert²⁰²¹,Feys Hendrik B³,van der Schoot C Ellen²,Harvala Heli²²²³

Affiliation:

1. University of Oxford, Oxford, United Kingdom

2. Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Amsterdam, Netherlands

3. Transfusion Research Centre, Belgian Red Cross-Flanders, Ghent, Belgium

4. Department of Pathology, Faculty of Veterinary Medicine, Liège University, Liège, Belgium

5. Immune Response service, Sciensano, Brussels, Belgium

6. National Influenza Centre, Sciensano, Brussels, Belgium

7. KU Leuven, Rega Institute, Clinical and Epidemiological Virology, Leuven, Belgium

8. Vircell SL, Granada, Spain

9. Andalusian Network of Transfusion Medicine, Tissues and Cells, Sevilla, Spain

10. Virus and Microbiological Special Diagnostics, Statens Serum Institute, Copenhagen, Denmark

11. Tartu University Institute of Technology, Tartu, Estonia

12. Institute of Microbiology and Immunology, Ljubljana, Slovenia

13. Centre for Infectious Disease Control, WHO COVID-19 Reference Laboratory, RIVML, Bilthoven, the Netherlands

14. Dep. of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway

15. Etablissement Français du Sang, La Plaine Saint Denis, France

16. Unité des Virus Émergents (Aix-Marseille University – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France

17. Etablissement français du Sang Provence Alpes Côte d’Azur et Corse, Marseille, France

18. Centre de Transfusion Sanguine des Armées, Clamart, France

19. Unité de Virologie, Institut de Recherche Biomédicale des Armées, Marseille, France

20. Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Wurttemberg – Hessen and University Hospital Ulm, Ulm, Germany

21. Department of Transfusion Medicine, Ulm University, Ulm, Germany

22. University College of London, London, United Kingdom

23. Microbiology Services, NHS Blood and Transplant, Colindale, United Kingdom

Abstract

We compared the performance of SARS-CoV-2 neutralising antibody testing between 12 European laboratories involved in convalescent plasma trials. Raw titres differed almost 100-fold differences between laboratories when blind-testing 15 plasma samples. Calibration of titres in relation to the reference reagent and standard curve obtained by testing a dilution series reduced the inter-laboratory variability ca 10-fold. The harmonisation of neutralising antibody quantification is a vital step towards determining the protective and therapeutic levels of neutralising antibodies.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference18 articles.

1. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection.;Kellam;J Gen Virol,2020

2. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.;Wajnberg;Science,2020

3. Correlates of protection against SARS-CoV-2 in rhesus macaques.;McMahan;Nature,2021

4. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.;Rogers;Science,2020

5. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.;Khoury;Nat Med,2021

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dosing of Convalescent Plasma and Hyperimmune Anti-SARS-CoV-2 Immunoglobulins: A Phase I/II Dose-Finding Study;Clinical Pharmacokinetics;2024-03-01

2. Comparative study between virus neutralisation testing and other serological methods detecting anti-SARS-CoV-2 antibodies in Europe, 2021;Journal of Virological Methods;2023-12

3. Preclinical evaluation of a SARS-CoV-2 variant B.1.351-based candidate DNA vaccine;Vaccine;2023-10

4. Quality assessment and harmonization of laboratories across Europe for multiple SARS‐CoV‐2 serology assays;Vox Sanguinis;2023-07-04

5. Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters;eBioMedicine;2023-06